UNASSIGNED: A 12-week randomized, double-blind, two-arm pilot feasibility trial of adults with comorbid ADHD and CUD (n = 28) comparing MAS-ER (80 mg) to placebo. Main outcomes: ADHD: ≥30% symptom reduction, measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS). CUD: Abstinence during last 2 observed weeks of maintenance phase.
UNASSIGNED: Overall, medication was well-tolerated. There was no significant difference in ADHD symptom reduction (MAS-ER: 83.3%; placebo: 71.4%; p = .65) or cannabis abstinence (MAS-ER: 15.4%; placebo: 0%; p = .27). MAS-ER group showed a significant decrease in weekly cannabis use days over time compared to placebo (p < .0001).
UNASSIGNED: MAS-ER was generally well-tolerated. The small sample size precluded a determination of MAS-ER\'s superiority reducing ADHD symptoms or promoting abstinence. Notably, MAS-ER significantly reduced weekly days of use over time.
■一项为期12周的随机研究,双盲,针对患有ADHD和CUD的成人(n=28)进行的双臂试点可行性试验,比较MAS-ER(80mg)和安慰剂。主要结果:ADHD:症状减轻≥30%,通过成人ADHD研究者症状评定量表(AISRS)进行测量。CUD:在维持阶段的最后2周观察期间禁欲。
■总的来说,药物耐受性良好。ADHD症状减轻(MAS-ER:83.3%;安慰剂:71.4%;p=0.65)或大麻禁欲(MAS-ER:15.4%;安慰剂:0%;p=0.27)没有显着差异。与安慰剂相比,MAS-ER组显示每周大麻使用天数随时间显着减少(p<0.0001)。
■MAS-ER一般耐受性良好。样本量小,无法确定MAS-ER的优越性,从而减轻ADHD症状或促进禁欲。值得注意的是,随着时间的推移,MAS-ER显著减少了每周的使用天数。